Aflac AFL Cancer — Capitalization
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aflac in its filing.
Tagged under the XBRL concept us-gaap:DeferredPolicyAcquisitionCostsAdditions.
The official record: Aflac’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aflac's cancer — capitalization.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aflac's cancer — capitalization?
- Aflac (AFL) reported cancer — capitalization of $80M in Q1 2026.
- How has Aflac's cancer — capitalization changed year-over-year?
- Aflac's cancer — capitalization increased by 31.1% year-over-year, from $61M to $80M.
- What is the long-term trend for Aflac's cancer — capitalization?
- Over 3 years (2022 to 2025), Aflac's cancer — capitalization has grown at a 7.1% compound annual growth rate (CAGR), from $291M to $357M.
- What does cancer — capitalization mean?
- Refers to the amount of acquisition-related expenses deferred and added to the balance sheet during the period for the cancer insurance segment. This reflects the initial investment made to secure new policyholders.